MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schrenk, D.
Right arrow Articles by Henschler, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schrenk, D.
Right arrow Articles by Henschler, D.

Metabolism and excretion of S-conjugates derived from hexachlorobutadiene in the isolated perfused rat kidney

D Schrenk, W Dekant and D Henschler

Institut fur Toxikologie, Universitat Wurzburg, Federal Republic of Germany.

Renal processing of the S-conjugates derived from hexachlorobutadiene (HCBD), S-(pentachlorobutadienyl)glutathione (PCBG), and S- (pentachlorobutadienyl)-L-cysteine (PCBC) was studied in the isolated perfused rat kidney. At an initial perfusate concentration of 20 microM, both conjugates were rapidly eliminated from the perfusate. Calculation of the fractional clearance rates revealed the dominant role of nonfiltering mechanisms in this process. This was confirmed by the strong inhibitory effect of 50 microM probenecid. S- (Pentachlorobutadienyl)-N-acetyl-L-cysteine (N-Ac-PCBC) was detected as the major metabolite of both PCBG and PCBC in urine and perfusate. PCBC and S-(pentachlorobutadienyl)cysteinylglycine were minor urinary metabolites formed from PCBG; only N-Ac-PCBC and PCBC were detected in the perfusate. At an initial S-conjugate concentration of 100 microM in the perfusate, the rate of elimination of both PCBG and PCBC continuously decreased during the perfusion, mainly as the result of a reduced excretion of N-Ac-PCBC. This indicates marked disturbance of N- acetylation and/or transport under these conditions. Addition of probenecid resulted in a significantly reduced renal elimination of both S-conjugates, predominantly due to a reduced rate of mercapturate excretion. In contrast, the nephrotoxicity of PCBC or PCBG was not significantly influenced by probenecid. It is concluded from these experiments that the kidney has the capacity to metabolize HCBD S- conjugates and that nonfiltering excretion of the mercapturic acid plays a decisive role. The pathways of HCBD S-conjugate metabolism in the kidney were shown to be dependent on their initial concentrations in the perfusate, most probably as a consequence of concentration- dependent toxic disturbances of transport and/or N-acetylation.

Volume 34, Issue 3, pp. 407-412, 09/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics